Bisphosphonates in renal cell carcinoma: Palliation versus antitumor effects

Saby George, Roberto Pili

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Management of bone metastases from renal cell carcinoma (RCC) is a challenge compared with some other malignancies. The management involves multidisciplinary approaches. The mainstay of therapy aimed at bone metastases is bisphosphonates and other agents that stabilize osteoclasts. Large trials of bisphosphonates demonstrated benefit in terms of preventing or delaying skeletal-related events and the associated comorbidities related to bone metastases. The limited disease-specific data in RCC suggest that there is benefit from bisphosphonates in delaying skeletal-related events and reducing symptoms. While the role of bisphosphonates remain largely palliative, it is interesting to note that there has been demonstration of direct antitumoral and antiangiogenic effects secondary to bisphosphonate use. Combining tyrosine kinase inhibitors with bisphosphonates is an area that needs to be studied extensively to evaluate the potential for any synergy and any safety issues in RCC patients.

Original languageEnglish (US)
Title of host publicationTargeted Therapies for Renal Cell Carcinoma
PublisherFuture Medicine Ltd.
Pages121-125
Number of pages5
ISBN (Electronic)9781780840024
ISBN (Print)9781780841014
DOIs
StatePublished - Oct 1 2011
Externally publishedYes

Fingerprint

Diphosphonates
Renal Cell Carcinoma
Neoplasm Metastasis
Bone and Bones
Osteoclasts
Protein-Tyrosine Kinases
Comorbidity
Safety
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

George, S., & Pili, R. (2011). Bisphosphonates in renal cell carcinoma: Palliation versus antitumor effects. In Targeted Therapies for Renal Cell Carcinoma (pp. 121-125). Future Medicine Ltd.. https://doi.org/10.2217/EBO.11.3

Bisphosphonates in renal cell carcinoma : Palliation versus antitumor effects. / George, Saby; Pili, Roberto.

Targeted Therapies for Renal Cell Carcinoma. Future Medicine Ltd., 2011. p. 121-125.

Research output: Chapter in Book/Report/Conference proceedingChapter

George, S & Pili, R 2011, Bisphosphonates in renal cell carcinoma: Palliation versus antitumor effects. in Targeted Therapies for Renal Cell Carcinoma. Future Medicine Ltd., pp. 121-125. https://doi.org/10.2217/EBO.11.3
George S, Pili R. Bisphosphonates in renal cell carcinoma: Palliation versus antitumor effects. In Targeted Therapies for Renal Cell Carcinoma. Future Medicine Ltd. 2011. p. 121-125 https://doi.org/10.2217/EBO.11.3
George, Saby ; Pili, Roberto. / Bisphosphonates in renal cell carcinoma : Palliation versus antitumor effects. Targeted Therapies for Renal Cell Carcinoma. Future Medicine Ltd., 2011. pp. 121-125
@inbook{12a1679820cd489e92a24e3187701caa,
title = "Bisphosphonates in renal cell carcinoma: Palliation versus antitumor effects",
abstract = "Management of bone metastases from renal cell carcinoma (RCC) is a challenge compared with some other malignancies. The management involves multidisciplinary approaches. The mainstay of therapy aimed at bone metastases is bisphosphonates and other agents that stabilize osteoclasts. Large trials of bisphosphonates demonstrated benefit in terms of preventing or delaying skeletal-related events and the associated comorbidities related to bone metastases. The limited disease-specific data in RCC suggest that there is benefit from bisphosphonates in delaying skeletal-related events and reducing symptoms. While the role of bisphosphonates remain largely palliative, it is interesting to note that there has been demonstration of direct antitumoral and antiangiogenic effects secondary to bisphosphonate use. Combining tyrosine kinase inhibitors with bisphosphonates is an area that needs to be studied extensively to evaluate the potential for any synergy and any safety issues in RCC patients.",
author = "Saby George and Roberto Pili",
year = "2011",
month = "10",
day = "1",
doi = "10.2217/EBO.11.3",
language = "English (US)",
isbn = "9781780841014",
pages = "121--125",
booktitle = "Targeted Therapies for Renal Cell Carcinoma",
publisher = "Future Medicine Ltd.",

}

TY - CHAP

T1 - Bisphosphonates in renal cell carcinoma

T2 - Palliation versus antitumor effects

AU - George, Saby

AU - Pili, Roberto

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Management of bone metastases from renal cell carcinoma (RCC) is a challenge compared with some other malignancies. The management involves multidisciplinary approaches. The mainstay of therapy aimed at bone metastases is bisphosphonates and other agents that stabilize osteoclasts. Large trials of bisphosphonates demonstrated benefit in terms of preventing or delaying skeletal-related events and the associated comorbidities related to bone metastases. The limited disease-specific data in RCC suggest that there is benefit from bisphosphonates in delaying skeletal-related events and reducing symptoms. While the role of bisphosphonates remain largely palliative, it is interesting to note that there has been demonstration of direct antitumoral and antiangiogenic effects secondary to bisphosphonate use. Combining tyrosine kinase inhibitors with bisphosphonates is an area that needs to be studied extensively to evaluate the potential for any synergy and any safety issues in RCC patients.

AB - Management of bone metastases from renal cell carcinoma (RCC) is a challenge compared with some other malignancies. The management involves multidisciplinary approaches. The mainstay of therapy aimed at bone metastases is bisphosphonates and other agents that stabilize osteoclasts. Large trials of bisphosphonates demonstrated benefit in terms of preventing or delaying skeletal-related events and the associated comorbidities related to bone metastases. The limited disease-specific data in RCC suggest that there is benefit from bisphosphonates in delaying skeletal-related events and reducing symptoms. While the role of bisphosphonates remain largely palliative, it is interesting to note that there has been demonstration of direct antitumoral and antiangiogenic effects secondary to bisphosphonate use. Combining tyrosine kinase inhibitors with bisphosphonates is an area that needs to be studied extensively to evaluate the potential for any synergy and any safety issues in RCC patients.

UR - http://www.scopus.com/inward/record.url?scp=84956832810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956832810&partnerID=8YFLogxK

U2 - 10.2217/EBO.11.3

DO - 10.2217/EBO.11.3

M3 - Chapter

AN - SCOPUS:84956832810

SN - 9781780841014

SP - 121

EP - 125

BT - Targeted Therapies for Renal Cell Carcinoma

PB - Future Medicine Ltd.

ER -